Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Background: Tolvaptan is the gold standard treatment for autosomal dominant polycystic kidney disease (ADPKD), while several other drugs have the potential to inhibit the progression of ADPKD. However, individual clinical trials may not show sufficient differences in clinical efficacy due to small s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukamoto, Shunichiro, Urate, Shingo, Yamada, Takayuki, Azushima, Kengo, Yamaji, Takahiro, Kinguchi, Sho, Uneda, Kazushi, Kanaoka, Tomohiko, Wakui, Hiromichi, Tamura, Kouichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158498/
https://www.ncbi.nlm.nih.gov/pubmed/35662736
http://dx.doi.org/10.3389/fphar.2022.885457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158498/
https://www.ncbi.nlm.nih.gov/pubmed/35662736
http://dx.doi.org/10.3389/fphar.2022.885457

Ejemplares similares